Oxurion NV (GB:0G99) has released an update.
Oxurion NV has received a transparency notification from Atlas Special Opportunities, LLC, revealing that Atlas has reduced its stake in Oxurion by selling shares and falling below the 15% ownership threshold. This move highlights the dynamic changes in shareholder composition for the biopharmaceutical company, which focuses on developing therapies for retinal diseases.
For further insights into GB:0G99 stock, check out TipRanks’ Stock Analysis page.